VR Logo

Intercept Pharmaceuticals Inc. (ICPT) download report


Healthcare | Biotechnology & Pharma Research

Intercept Pharmaceuticals Inc. (ICPT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

IPO Date: 11-Oct-2012

Pres, CEO & Director: Mr. Jerome B. Durso

Chief Financial Officer: Mr. Andrew Saik

Listing: NASDAQ: ICPT

Country: United States

Headquarters: New York, NY

Website: https://www.interceptpharma.com

Key Facts

Market cap: $419.85 Mln

Revenue (TTM): $370.39 Mln

Earnings (TTM): $-68.29 Mln

Cash: $395.70 Mln

Total Debt: $725.73 Mln

Insider's Holding: 4.50%

Liquidity: Low

52 Week range: $10.81 - 20.50

Shares outstanding: 29,713,100

10 Years Aggregate:

  • CFO: $-1,591.23 Mln
  • EBITDA: $-2,062.34 Mln
  • Net Profit: $-2,414.52 Mln

Stock Performance

Time Period Intercept Pharmaceuticals (ICPT) S&P BSE Sensex* S&P Small-Cap 600*
YTD-13.26-8.62-18.78
1 month-23.91-4.54-8.00
3 months-13.15-10.19-13.65
1 Year-29.241.43-17.19
3 Years-43.7910.146.10
5 Years-34.9211.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Intercept Pharmaceuticals (ICPT) S&P Small-Cap 600 S&P BSE Sensex
2021-34.0525.2721.99
2020-80.079.5715.75
201922.9520.8614.38
201872.01-9.705.87
2017-46.2311.7327.91
2016-27.2524.741.95
2015-4.26-3.36-5.03